MedTrace Logo

Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis

NCT04450030 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 204

Last updated 2020-11-12

No results posted yet for this study

Summary

Treatment of acute relapsing multiple sclerosis (MS) has remained largely unaltered within past years. However, evidence defining the exact role of apheresis treatment in the therapeutic sequence is still incomplete. INCIDENT-MS evaluates the mechanism of action of immunoadsorption compared to escalated methyl prednisolone treatment in steroid-refractory MS relapses and thereby will help to identify predictive markers for optimal treatment choice and will generate further insights into the pathophysiology of MS relapses.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Methyl Prednisolonate

2000mg intravenous methyl prednisolone per day for five consecutive days

PROCEDURE

Immunoadsorption

6 courses of tryptophane-based immunoadsorption within up to 12 days

Sponsors & Collaborators

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Sven G Meuth, Prof Dr · University Hospital Muenster, Department of Neurology

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2020-09-05
Completion
2020-12-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04450030 on ClinicalTrials.gov